ADVANCES IN VACCINE DEVELOPMENT USING MRNA TECHNOLOGY: LESSONS FROM THE COVID-19 PANDEMIC

Abstract

The growth of mRNA vaccine technology led huge changes in health protection and immunology fields because of COVID-19. Our review focuses on important MRI vaccine advances especially from COVID-19related experiments. Pfizer-BioNTech and Moderna developed mRNA vaccines that give excellent protection while being safe which lets these companies offer rapid production options at scale. Because mRNA vaccines can be developed in one week this new vaccine platform remains more exposed to emerging health threats than standard vaccines. The development of vaccines against multiple diseases including cancer and influenza has become achievable because of how well mRNA vaccines work against SARS-CoV-2. Although success has been made many challenges persist particularly with maintaining mRNA stability during distribution. The paper examines how nanoparticles particularly lipid nanoparticles (LNPs) increase the delivery of mRNA vaccines. This paper examines how mRNA vaccines hold great potential for preventing infections and treating medical conditions particularly cancer. It has been concluded that the COVID-19 pandemic made the world see the revolution mRNA vaccines could create while also showing why these vaccines are better than traditional platforms. Although Pfizer-BioNTech and Moderna showed that their mRNA vaccines work well in trials they need modifications for better performance. Lipid nanoparticles became a critical method to solve delivery and stabilization challenges that come with mRNA vaccines. Next to fighting infectious diseases mRNA vaccines show promising benefits in treating cancer and improving custom treatment methods. The next stage of research must advance the performance of these vaccines for wider application. The creation of mRNA vaccines forms our best defense against emerging diseases as the world prepares for more outbreaks across nations.